ACCESS Newswire
25 May 2022, 18:07 GMT+10
Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children and leads to significant morbidity and mortality from severe secretory diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2022 / Jaguar Health (NASDAQ:JAGX) today announced that Napo Therapeutics, the Italian corporation established by the company in Italy in 2021 that focuses on expanding crofelemer access in Europe, has submitted an Orphan Drug Designation (ODD) application for crofelemer for a rare congenital diarrheal disorder (CDD) condition called microvillus inclusion disease (MVID) to the European Medicines Agency (EMA). The submission is the first step of the process; the review by the EMA's Committee for Orphan Medicinal Products (COMP) will start after the validation of the submission.
'CDDs are a group of inherited chronic enteropathies characterized by heterogeneous etiology, and each type of CDD is thus a different disease with a different pathogenetic mechanism,' said Martire Particco, MD, Chief Medical Officer of Napo Therapeutics. 'MVID is a life-threatening and rare autosomal recessive disease that affects newborns and children and leads to significant morbidity and even death from severe secretory diarrhea.'
CDDs share a primary common symptom: chronic diarrhea, and therefore secondary symptoms associated with diarrhea, including significant dehydration, metabolic acidosis or alkalosis and malnutrition, among other secondary symptoms, and these symptoms expeditiously emerge and become life-threatening.
Napo Therapeutics' mission is to provide access to Jaguar Health's proprietary first-in-class plant-based medicine crofelemer in Europe to address such significant rare disease indications. The company's initial focus is on clinical development and future registration in Europe of crofelemer for debilitating orphan disease target indications starting with short bowel syndrome (SBS).
The evaluation process for the ODD application takes approximately 90 days from acceptance. Sponsors who obtain orphan designation for their drug can benefit from Scientific Advice from the EMA for clinical trials for the orphan indication and receive market exclusivity for a period of ten years once the medicine is approved for commercialization.
'We are very pleased that the orphan drug designation application for crofelemer for MVID is now with the EMA,' said Massimo Mineo, CEO of Napo Therapeutics. 'Upon receipt of a positive opinion from the COMP on this application, crofelemer will be eligible for granting of orphan drug designation by the EMA for this indication. Receipt of orphan drug designation would support some specific regulatory pathways for this serious form of CDD, which represents a significant unmet medical need.'
About Crofelemer
Crofelemer is a botanical (plant-based) drug extracted and purified from the red bark sap, also referred to as 'dragon's blood,' of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, Jaguar Health's wholly owned U.S. subsidiary, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.
About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals, & Napo Therapeutics
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com.
Forward-Looking Statements
Certain statements in this press release constitute 'forward-looking statements.' In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
Peter Hodge
Jaguar Health, Inc.
[email protected]
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
Get a daily dose of Vancouver Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Vancouver Star.
More InformationWASHINGTON, D.C.: The largest firefighters' union in the United States is calling for federal antitrust authorities to investigate...
LOS ANGELES, California: One person died and 32 others were hurt when a tour bus and an SUV crashed on a freeway near Los Angeles over...
COLOMBO, Sri Lanka: A passenger bus carrying nearly 50 people skidded off a cliff in Sri Lanka's central highlands, killing 21 and...
WASHINGTON, D.C.: U.S. President Donald Trump signed an executive order this week to lower the cost of prescription drugs in the United...
PASADENA, California: A U.S. appeals court late last week upheld a federal law that stops felons from owning guns. The court rejected...
MOUNTAIN VIEW, California: Google will pay US$1.4 billion to settle allegations that it unlawfully collected user data in Texas without...
NEW YORK, New York - U.S. stocks closed higher Friday with all the major indices capping weekly gains in the process. Markets are...
WASHINGTON, D.C.: The U.S. Department of Energy has announced plans to eliminate or amend more than 40 regulations as part of President...
WASHINGTON, D.C.: In April, U.S. consumer prices went up slightly. Rent costs increased, but food prices went down, which helped keep...
NEW YORK - International travel spending in the United States is projected to decline by 7 percent in 2025, amounting to a US$12.5...
NEW YORK, New York - U.S. stocks were mostly higher Thursday, although the Nasdaq Composite finished modestly behind. This is a market...
SAN JUAN, Puerto Rico: As the global trade war deepens, Puerto Rico is seizing the moment to lure international companies to relocate...